Quazepam Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 7.5 mg, 15 mg, 30 mg
Reference Brands: Doral (USA/EU)
Category:
Antipsychotropic Drugs
Quazepam is available in Capsules
and strengths such as 7.5 mg, 15 mg, 30 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Quazepam is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Quazepam can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Quazepam is a long-acting benzodiazepine derivative developed by Schering Corporation, primarily used for the treatment of insomnia. Marketed under the brand name Doral, it is effective in both sleep induction and sleep maintenance, helping patients achieve restorative sleep without disrupting normal sleep architecture. Quazepam selectively targets specific GABA-A receptor subtypes, which provides hypnotic and anticonvulsant effects while minimizing the risk of overdose compared to other benzodiazepines.
Quazepam is particularly useful for short-term management of insomnia, demonstrating superior efficacy over other hypnotics like temazepam. Clinical studies have shown it to have a lower incidence of side effects, including less daytime sedation, amnesia, and motor impairment. It works by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system, promoting relaxation and sustained sleep.
The medication is administered orally, typically at a dosage of 7.5 to 15 mg at bedtime, and should be used under medical supervision due to its sedative properties. Quazepam is a preferred choice for patients who require effective sleep support with minimal next-day impairment, making it a valuable option in the management of insomnia.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing